NAMSW (STOCKS)
NewAmsterdam Pharma Company N.V. Warrant
—
Change: —
Prev close: —
Company Information
- Exchange
- XNAS
- Sector
- —
- Industry
- —
- CEO
- —
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- —
- Employees
- 77
- P/E (TTM)
- —
- P/B (TTM)
- —
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $7.12M |
| Benefits Costs and Expenses | $266.63M |
| Costs And Expenses | $266.63M |
| Operating Expenses | $251.53M |
| Selling, General, and Administrative Expenses | $102.28M |
| Depreciation and Amortization | $484.00K |
| Research and Development | $149.25M |
| Operating Income/Loss | -$244.41M |
| Income/Loss From Continuing Operations After Tax | -$259.50M |
| Income/Loss From Continuing Operations Before Tax | -$259.50M |
| Net Income/Loss | -$259.50M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$259.50M |
| Net Income/Loss Available To Common Stockholders, Basic | -$259.50M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.16 |
| Diluted Earnings Per Share | -$2.16 |
| Basic Average Shares | 364,606,303 |
| Diluted Average Shares | 364,606,303 |
| Assets | $704.45M |
| Current Assets | $659.21M |
| Noncurrent Assets | $45.25M |
| Fixed Assets | $411.00K |
| Other Non-current Assets | $44.83M |
| Liabilities | $73.03M |
| Current Liabilities | $72.97M |
| Accounts Payable | $5.42M |
| Other Current Liabilities | $67.55M |
| Noncurrent Liabilities | $56.00K |
| Equity | $631.42M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $631.42M |
| Liabilities And Equity | $704.45M |
| Net Cash Flow From Operating Activities | -$143.46M |
| Net Cash Flow From Operating Activities, Continuing | -$143.46M |
| Net Cash Flow From Investing Activities | -$34.91M |
| Net Cash Flow From Investing Activities, Continuing | -$34.91M |
| Net Cash Flow From Financing Activities | $41.68M |
| Net Cash Flow From Financing Activities, Continuing | $41.68M |
| Net Cash Flow | -$136.69M |
| Net Cash Flow, Continuing | -$136.69M |
| Comprehensive Income/Loss | -$259.97M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$259.97M |
| Other Comprehensive Income/Loss | -$72.47M |